Drug Trial Radar · NCT02112994
Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency
Last checked: Nov 20, 2026Latest source record: Dec 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Jun 24, 2014
Primary completion
Dec 28, 2017
Study completion Dec 28, 2017
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency (LAL-D).
Conditions
- Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase AlfaDrug
IV infusion of sebelipase alfa
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)Time frame: Screening, Week 144
Locations
19 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Chicago, Illinois
Site not named
Shreveport, Louisiana
Site not named
Cincinnati, Ohio
Site not named
Westmead, Australia
Site not named
Brussels, Belgium
Site not named
São Paulo, Brazil
Site not named
Halifax, Nova Scotia, Canada
Site not named
Zagreb, Croatia
Site not named
Copenhagen, Denmark
Site not named
Freiburg im Breisgau, Germany
Site not named
Padova, Italy
Site not named
Mexico City, Mexico
Site not named
Amsterdam, Netherlands
Site not named
Moscow, Russia
Site not named
A Coruña, Spain
Site not named
Barcelona, Spain
Site not named
Madrid, Spain
Site not named
Balcalı, Turkey (Türkiye)
Site not named
Birmingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.